Hearing Supplement Guide: What The Evidence Shows

Before any ingredient is worth discussing, one document has to be on the table. The American Academy of Otolaryngology–Head and Neck Surgery Foundation clinical practice guideline on tinnitus tells clinicians they should not recommend dietary supplements for patients with persistent bothersome tinnitus. The guideline’s own plain-language summary says the same thing in fewer words.

That is not a fringe position or an old one. It is the professional body for ear, nose and throat medicine, addressing exactly the symptom this shelf is stocked for, and it reached that recommendation by reading the same trials this guide is about to walk through.

The reason to say it first rather than bury it is that everything below reads differently once it is in place. A guide that surveys twenty ingredients without mentioning the guideline is inviting a reader to conclude that the evidence is unsettled. It is settled enough for a recommendation.

Five of the six are negative, null or narrow. The sixth is not an ingredient any capsule on this shelf can deliver the way the study did.

Read that table twice, because the shape of it is the whole guide. The ingredient with the most convincing result, folate, is the one least often found on these panels. The ingredient most often found on them, zinc, is the one with a four-month trial concluding it does not work.

It is worth being precise about what a negative trial means. The zinc crossover trial gave 50 mg a day, four times what a typical multivitamin carries, and reported that zinc was not effective. The Cochrane review pooled three studies and concluded there was no evidence to say either way, which is a statement about the quality of the evidence rather than a verdict of harm.

The ginkgo review is the same story with a different plant. Ginkgo is the single most-sold tinnitus botanical in the world and its own systematic review does not support the use it is sold for.

The folic acid trial deserves the attention the others get. Three years, 800 mcg a day, in a population with low folate intake, measuring age-related hearing decline rather than ringing. It is a different endpoint and it is the best-conducted study in this whole survey.

Magnesium is the one on the list whose evidence is most often overstated, and the overstatement is a category error rather than a fabrication.

The trial people are thinking of gave 167 mg a day to people about to be exposed to loud noise, and looked at whether it protected hearing through that exposure. A second line of work looked at magnesium alongside treatment for sudden hearing loss, which is an emergency handled in a clinic.

Neither is a study of somebody who has had a ringing in their ears for two years. Protecting an ear during an insult and quieting an ear afterwards are separate questions with separate answers, and a panel carrying magnesium is borrowing the reputation of the first to sell the second.

The dose matters as much as the setting. 167 mg a day is a substantial amount, and it is roughly thirteen times what a typical blended formula in this aisle carries. Where the form is magnesium oxide, which is the least absorbable of the common salts, the practical gap is wider than the arithmetic suggests.

Most formulas in this aisle are not really built from the six ingredients above. Open a panel and what you usually find is a calm-and-sleep stack: valerian, hops, passion flower, chamomile, lemon balm, GABA, L-theanine, magnolia, 5-HTP, ashwagandha.

That is a different proposition and it deserves to be judged as one rather than dismissed. Ringing is worse in a quiet room, worse when you are tired, and worse when you are anxious about it, and none of those observations is controversial. A formula aimed at sleep and at arousal is aiming at something real.

The evidence for that group is mixed and mostly modest. An umbrella review of valerian covers the sleep literature, the chamomile trial ran in generalised anxiety at 1,500 mg a day, the ashwagandha meta-analysis pools the anxiety work, and the L-theanine trial used 200 mg a day over four weeks.

Two cautions belong with the group. The first is dose: those trials used hundreds of milligrams of single ingredients, and a blend splitting a few hundred milligrams across fifteen names is not delivering any of them at trial strength. The second is that reviews of herbal insomnia remedies and reviews of herbal anxiolytics both conclude that the literature is thinner and lower in quality than the shelf implies.

St John’s wort is the first, and it is the most consequential ingredient on this whole shelf for reasons that have nothing to do with ears. It induces the enzymes and transporters that clear a long list of prescription medicines, which means it can quietly lower the concentration of a drug somebody is relying on. Hormonal contraception is the best-documented example, and NCCIH publishes a plain summary of the rest.

5-HTP is the second, and it matters mostly when it is found beside the first. It is a serotonin precursor, with its own literature, and two serotonergic ingredients in one capsule is worth naming to anybody already taking an antidepressant.

Neither of those is a reason to be frightened of a bottle. They are a reason to read a panel before swallowing it and to mention it at the next appointment, which is ordinary practice with any supplement and is not always as easy as it sounds when the ingredients are pooled inside a blend line.

A third, smaller one: zinc. Sustained high intake affects copper status, as the toxicity literature sets out, so the number to watch is the total across everything you take rather than the figure on any one panel.

A dietary supplement sold in the United States may carry a structure or function claim, a sentence about supporting a body part, provided it does not claim to treat a disease. Tinnitus is a symptom with disease causes behind it, which makes the permissible sentence narrow and the impermissible one obvious.

So the labels hedge, and they hedge in a recognisable pattern: a word like support, an organ named vaguely, and a disclaimer beneath. Some go further and print nothing at all, letting a waveform or an ear-shaped mark carry the suggestion that the words avoid.

The regulator has acted where the hedging stops. The FDA has warned consumers about products sold as tinnitus cures, and a 2026 review of over-the-counter tinnitus products documents how common the practice remains.

The practical reading is simple. A vague claim is not evidence of a weak product, and a bold claim is evidence of a problem. What a label prints tells you about its legal caution rather than its contents, and the panel is where the contents are.

One further consequence is worth carrying into the next guide. Where a label claims nothing at all, there is nothing to hold it to, and the ceiling on what a retailer may say has to come from the category instead. That is why the guideline at the top of this page does so much work on this website.

A guide that spends nine sections on what does not work owes the reader a paragraph on what the evidence does support, even though none of it is sold in a bottle.

The clinical practice guideline recommends education and counselling as a first step, so that somebody understands what they are hearing. It recommends a hearing evaluation and, where there is hearing loss, hearing aids, which frequently reduce how intrusive a ringing is. It supports sound therapy as an option and cognitive behavioural therapy where the distress is significant.

Population work on how common tinnitus is puts those recommendations in context: this is a very widespread symptom, most of it mild, and a substantial part of the distress is about attention and sleep rather than about the sound itself.

Surveys of supplement use in this population find that a great many people try a capsule first, which is understandable: it is available, it is private and it requires nobody’s permission. The honest note to end on is that it is the step with the least behind it, not the most.